Page last updated: 2024-11-04

n-formylmethionylphenylalanine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

n-Formylmethionylphenylalanine (fMet-Phe) is a dipeptide that plays a crucial role in protein synthesis in bacteria. It is the first amino acid incorporated into a polypeptide chain during translation, serving as a start signal. The formyl group on the methionine residue is essential for the initiation of protein synthesis. The synthesis of fMet-Phe involves the attachment of a formyl group to the amino group of methionine, followed by the addition of phenylalanine. fMet-Phe has been studied extensively in the context of bacterial protein synthesis. It is a target for antibiotics that inhibit translation, such as puromycin. Research on fMet-Phe has also led to the development of methods for studying protein synthesis in bacteria. fMet-Phe is also used in studies of protein folding and stability. The importance of fMet-Phe lies in its role as a critical initiator in bacterial protein synthesis, making it a potential target for antimicrobial drugs. Furthermore, its study provides insights into the mechanisms of protein synthesis and the development of new therapeutic strategies.'

Cross-References

ID SourceID
PubMed CID4365
CHEBI ID111175
SCHEMBL ID3382813
MeSH IDM0068030

Synonyms (27)

Synonym
BRD-A09975616-001-02-3
KBIO1_000498
DIVK1C_000498
SPECTRUM_001318
n-formylmethionylphenylalanine
IDI1_000498
NCGC00178577-01
SPECTRUM5_001071
BSPBIO_002608
KBIO2_006934
KBIOGR_001887
KBIO2_001798
KBIOSS_001798
KBIO2_004366
KBIO3_001828
SPECTRUM2_001193
SPECTRUM3_001054
NINDS_000498
SPECTRUM4_001194
SPBIO_001265
CHEBI:111175
HMS501I20
SCHEMBL3382813
CCG-40320
FT-0638173
2-[[2-formamido-4-(methylthio)-1-oxobutyl]amino]-3-phenylpropanoic acid
Q27190675

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Time- and dose-response relationships for neutrophil bipolar shape formation (BSF) agree with data reported for other neutrophil response measurements."( Neutrophil bipolar shape formation in whole blood. A simple and rapid method for the assessment of neutrophil leukocyte responsiveness.
Jadwin, DF; Meadows, TR; Smith, CW, 1981
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
peptideAmide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-199040 (78.43)18.7374
1990's7 (13.73)18.2507
2000's1 (1.96)29.6817
2010's3 (5.88)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.72 (24.57)
Research Supply Index3.99 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.92%)5.53%
Reviews1 (1.92%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other50 (96.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]